CKDXF (Opthea) Tariff Resilience Score: 5/10 (As of Jul. 01, 2026)


What is Opthea Tariff Resilience Score?

Opthea CKDXF Tariff Resilience Score is 5 as of Jul. 01, 2026. The stock has 3 warning signs investors should review. Among 1,374 Biotechnology companies, Opthea ranks better than 62.23% on this metric.

Opthea has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Opthea has Biotechnology firm with international supply chain dependencies. Tariffs on pharmaceutical imports/exports could impact costs, but industry-specific exemptions may provide some relief.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Opthea might have Average Resilient.

Opthea  (OTCPK:CKDXF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Opthea Tariff Resilience Score Related Terms

CKDXF vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Opthea's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opthea Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opthea's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Opthea's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 5 mean?
Opthea (CKDXF) has a Tariff Resilience Score of 5 as of Jul. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Opthea ranks #519 out of 1374 companies in the Biotechnology industry, placing it in the top 37.8%.
Is Opthea's Tariff Resilience Score too high?
Opthea's current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Opthea's value of 5 is 25% above this industry median. Based on the distribution chart, Opthea ranks #519 out of 1374 companies in the Biotechnology industry, which is above the industry midpoint.
How does Opthea's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Opthea ranks #519 out of 1374 companies for Tariff Resilience Score. This puts Opthea in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Opthea's value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Opthea's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Opthea's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opthea stock overvalued right now?
Opthea (CKDXF) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Opthea (CKDXF), the current Tariff Resilience Score is 5 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Opthea Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.